Robert W Snyder, MD, PhD, PC Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03022318
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

carbidopa (sinemet) (3 trials)

levodopa (larodopa) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2